Motivation, Syringe Exchange, and COVID-19

NCT05534061 | Completed Results

• 2 other identifiers: 11162020.013b1U01DA055982-01
• Study Type: interventional
• Target: 349
• Locations: 1 country
• Sites: 1

Brief Summary

People who inject drugs (PWIDs) are highly vulnerable to SARS-CoV-2 infection and to the disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), however, rates of SARS-CoV-2 testing and vaccination uptake -vital to mitigating the spread of COVID-19 and achieving herd immunity - are lower among PWIDs compared to the general population. Building on our Phase I Rapid Acceleration of Diagnostics project, which found that contingency management (CM) increased testing utilization among PWIDs, the proposed project evaluates the comparative effectiveness of CM versus CM plus a brief motivational enhancement intervention on SARS-CoV-2 testing and vaccination uptake among PWIDs. This project has the potential to reduce COVID-19 health disparities among PWIDs and to decrease population level COVID-19 morbidity and mortality.

Conditions

COVID-19 Pandemic

Outcome Measures

Primary Outcomes (2)

• SARS-CoV-2 Testing

  Yes/no indicator (coded 1 = yes, 0 = no) of whether or not person was tested for SARS-CoV-2 testing at syringe exchange visit, data collected from medical record

  Immediate post intervention (i.e., same day)

• SARS-CoV-2 Testing

  Yes/no indicator (coded 1 = yes, 0 = no) of whether or not person was tested for SARS-CoV-2 testing at syringe exchange visit, data collected from medical record

  Up to 9-months after intervention

Secondary Outcomes (2)

• COVID-19 Vaccination

  Immediate post intervention (i.e., same day)

• COVID-19 Vaccination

  Up to 9-months after intervention

Study Arms (2)

Connect2Test Intervention + Contingency Management

EXPERIMENTAL

$10 financial incentive for vaccination and $10 financial incentive for testing plus a brief feedback-based motivational enhancement intervention.

Behavioral: Connect2Test

Contingency Management Alone

ACTIVE COMPARATOR

$10 financial incentive for vaccination and $10 financial incentive for testing.

Behavioral: Connect2Test

Interventions

Connect2Test BEHAVIORAL

Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients

Also known as: Motivational Enhancement

Connect2Test Intervention + Contingency Management; Contingency Management Alone

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• and older, understand English

You may not qualify if:

• none

Sponsors & Collaborators

• University of Oregon: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

University of Oregon

Eugene, Oregon, 97403, United States

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Results Point of Contact

• Title: Anne Marie Mauricio, PhD
• Organization: University of Oregon

amariem@uoregon.edu

602-920-7459

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 7, 2022
• First Posted: September 9, 2022
• Study Start: August 8, 2022
• Primary Completion: June 30, 2023
• Study Completion: June 30, 2023
• Last Updated: February 28, 2024
• Results First Posted: February 28, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF

Locations

US (1)